Novel anti-platelet therapy shows promise in first human trials New anti-platelet drug set for phase II study after success in patients with coronary heart disease.…
Filling the gap in mental health research Ways to tackle the lack of funding in mental health research.…
Hepatitis C project set for roll out after winning QiC award An award-winning project to improve access to hepatitis C testing and treatment in community pharmacy for patients addicted to opioid drugs is set to be extended over the next few months.…
Developing new psoriasis treatment regimens for patients based on their clinical profile Biologics and small-molecule drugs being developed to treat psoriasis are showing encouraging results, but high costs could limit their use.…
Asthma therapies get personal A new crop of biologic drugs promises to usher asthma treatment into the realm of personalised medicine.…
Closing in on Alzheimer’s disease Knowledge about the neuropathology of Alzheimer’s disease has blossomed over the past few decades, leading to a better understanding of the condition and new ways to attack it.…
Attacking cancer: are therapeutic vaccines on the verge of fulfilling their potential? Researchers are investigating whether priming the immune system with therapeutic vaccines can prompt the body’s own defences to spring into action against cancer.…
NICE’s assessment process is stifling pharmaceutical innovation The way new medicines are assessed should be reformed to provide patients with the best treatments and stimulate research and innovation in the UK.…
Drug development: the journey of a medicine from lab to shelf Before a drug is deemed suitable for patients, it has to go through rigorous testing and cost-effectiveness analyses.…
Olaparib halts tumour growth in advanced prostate cancer Olaparib, a drug approved for the treatment of women with ovarian cancer who have inherited BRCA mutations, also benefits men with prostate cancer.…